Key Takeaways
- Q2 net income reached $361.8 million, translating to $1.10 per diluted share, a dramatic turnaround from an 89-cent loss in the prior year period
- Total revenue climbed 70% annually to $4.88 billion, surpassing analyst expectations of $4.73 billion
- The medical loss ratio showed significant improvement at 79.2%, compared to 91.1% in the same quarter last year
- Management elevated full-year operating earnings outlook to $500 million-$700 million from the previous $250 million-$450 million range
- Despite crushing estimates, OSCR shares declined approximately 9% on Thursday following an 8.9% premarket surge
Oscar Health delivered what appeared to be a blowout quarterly performance on Thursday, yet investors responded by sending shares sharply lower.
OSCR plummeted roughly 9% during Thursday’s session, August 6, completely erasing a nearly 9% premarket rally. Shares had settled at $30.11 on Wednesday. Even with Thursday’s decline, the stock remains up an impressive 110% year-to-date in 2026, significantly outpacing the S&P 500’s 13% gain.
The health insurer delivered quarterly earnings of $1.10 per share, obliterating the Wall Street consensus estimate of 40 cents. Total revenue climbed 70% year-over-year to $4.88 billion, comfortably exceeding analyst projections of $4.73 billion.
Looking at the first six months of 2026, Oscar generated net income of $1.04 billion, equivalent to $3.16 per share. This represents a dramatic improvement from the $46.9 million earned during the comparable period in 2025.
Improved Medical Loss Ratio Takes Center Stage
The company’s medical loss ratio improved substantially to 79.2% during the second quarter, versus 91.1% in Q2 2025. This metric came in better than Wall Street’s 81.2% forecast, marking a significant operational win. Management attributed the improvement to strategic pricing discipline and $164 million from favorable adjustments to prior period reserves.
Oscar significantly boosted its full-year operating earnings projection to between $500 million and $700 million, nearly doubling the previous range of $250 million to $450 million. The company maintained its total revenue guidance at $18.7 billion to $19 billion.
The insurer’s membership base expanded to 2.9 million as of June 30, representing 46% growth compared to the prior year. This growth is particularly notable given that nationwide ACA enrollment contracted by approximately three million members after temporary federal subsidies lapsed late last year.
Major competitors like CVS Health’s Aetna withdrew from the ACA individual marketplace this year, while Cigna announced plans to exit in 2027. Oscar has taken the contrarian approach by expanding its presence.
Membership Attrition Concerns Emerge
What explains the stock’s decline after such strong results? Stephens analyst Raj Kumar pointed to potential membership attrition in the latter half of the year as a probable concern weighing on investor sentiment.
Enrollment had already experienced a modest decline from 3.2 million at the end of March to 2.96 million by June 30. During the earnings conference call, CEO Mark Bertolini acknowledged expectations for “further market contraction” ahead.
Kumar highlighted that possible attrition “could add additional risk” to the company’s outlook. For Oscar, which lacks the diversification of larger insurance competitors, the ACA marketplace represents its complete revenue base.
Baird analyst Michael Ha characterized the quarterly performance as “an important proof point for the earnings thesis,” while cautioning that maintaining a position in the stock demands conviction that the ACA marketplace “remains structurally viable as enrollment and market composition evolve.”
The consensus analyst rating on OSCR stands at Hold, with a mean price target of $26.09, based on FactSet data.
Bertolini expressed confidence that the company is moving into the second half of 2026 “from a position of strength, with the technology, scale, and operating discipline to deliver profitable growth.”
Notably, the Street’s average price target of $26.09 remains below the level at which shares were trading prior to Thursday’s selloff.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
